{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:44:49Z","timestamp":1790315089319,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,7,20]],"date-time":"2015-07-20T00:00:00Z","timestamp":1437350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Hepatitis B immunoprophylaxis failure is linked to high maternal viraemia. There is limited North American data on hepatitis B outcomes in pregnancy. Pregnant hepatitis B carriers were enrolled January 2011\u2013December 2014 and offered tenofovir in the 3rd trimester if hepatitis B virus (<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>)\u2010<jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content>was &gt;7\u2010log IU\/mL. Outcomes were determined in treated<jats:italic>vs<\/jats:italic>untreated patients. In total, 161 women with 169 pregnancies (one twin, 170 infants; median age 32\u00a0years), 18% (29\/161)<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>eAg+ and median<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content>2.51 log<jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/mL (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content>1.66\u20133.65; range 0.8\u20138.1) were studied. 14.3% (23\/161) received tenofovir due to high viral load (16\/23, median 74\u00a0days,<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content>59\u2013110) or due to liver disease (7\/23). In 10\/16 treated due to high viraemia, with confirmed adherence, follow\u2010up<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content>showed a 5.49 log decline (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.003). In treatment na\u00efve mothers, median alanine aminotransferase (<jats:styled-content style=\"fixed-case\">ALT<\/jats:styled-content>) increased from 17<jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/L (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content>12\u201324) to 29 (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content>18\u201336) post\u2010partum (<jats:italic>P<\/jats:italic>\u00a0=\u00a01.5e\u20107). In seven highly viraemic mothers who declined therapy (<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content>&gt;8\u2010log<jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/mL); median<jats:styled-content style=\"fixed-case\">ALT<\/jats:styled-content>increased ~3X from baseline (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.01). 26% (44\/169) had Caesarean section with no difference in treated<jats:italic>vs<\/jats:italic>untreated subjects. No tenofovir\u2010treated mothers had renal dysfunction. Data were available on 167\/170 infants; in 50.8% (85\/167) who completed immunoprophylaxis, 98.8% (84\/85, including 12 exposed to tenofovir<jats:italic>in utero<\/jats:italic>) were<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>immune. One infant born to an<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>eAg+ mother with<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content>&gt;8\u2010log<jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/mL failed immunoprophylaxis. In this prospective Canadian cohort study, most untreated mothers experienced mild<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>flares. Tenofovir in pregnancy is well tolerated and reduces viral load prior to parturition.<\/jats:p>","DOI":"10.1111\/jvh.12436","type":"journal-article","created":{"date-parts":[[2015,7,20]],"date-time":"2015-07-20T11:28:50Z","timestamp":1437391730000},"page":"15-22","source":"Crossref","is-referenced-by-count":52,"title":["Clinical course of 161 untreated and tenofovir\u2010treated chronic hepatitis<scp>B<\/scp>pregnant patients in a low hepatitis<scp>B<\/scp>virus endemic region"],"prefix":"10.1111","volume":"23","author":[{"given":"G.","family":"Samadi Kochaksaraei","sequence":"first","affiliation":[{"name":"Calgary Liver Unit Division of Gastroenterology and Hepatology Cumming School of Medicine University of Calgary Calgary AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Castillo","sequence":"additional","affiliation":[{"name":"Medical Disorders in Pregnancy Division of Internal Medicine Cumming School of Medicine University of Calgary Calgary AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Osman","sequence":"additional","affiliation":[{"name":"Alberta Health Government of Alberta Edmonton AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Simmonds","sequence":"additional","affiliation":[{"name":"Alberta Health Government of Alberta Edmonton AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. N.","family":"Scott","sequence":"additional","affiliation":[{"name":"Alberta Health Government of Alberta Edmonton AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. I.","family":"Oshiomogho","sequence":"additional","affiliation":[{"name":"Calgary Liver Unit Division of Gastroenterology and Hepatology Cumming School of Medicine University of Calgary Calgary AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. S.","family":"Lee","sequence":"additional","affiliation":[{"name":"Calgary Liver Unit Division of Gastroenterology and Hepatology Cumming School of Medicine University of Calgary Calgary AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. P.","family":"Myers","sequence":"additional","affiliation":[{"name":"Calgary Liver Unit Division of Gastroenterology and Hepatology Cumming School of Medicine University of Calgary Calgary AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. R.","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Paediatrics Alberta Children's Hospital Calgary AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. S.","family":"Coffin","sequence":"additional","affiliation":[{"name":"Calgary Liver Unit Division of Gastroenterology and Hepatology Cumming School of Medicine University of Calgary Calgary AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,7,20]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"WHO.Hepatitis B: World Health Organization fact sheet 204(revised July 2014). Available athttp:\/\/www.who.int\/mediacentre\/factsheets\/fs204\/en. (accessed 15 November 2014)."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23190"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/151.4.599"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.09.056"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/epirev\/mxj009"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-006-0327-5"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.12.035"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2009.tb02524.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01492.x"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.11.008"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.08.034"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.010"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/506819"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.10.041"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2008.01056.x"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2003.00440.x"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510270634"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.032"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.01.019"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-014-3486-7"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2008.0263"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182a7adb2"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.06.031"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-012-2187-3"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.04.038"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i48.9377"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12726"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12793"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03403711"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-0913"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12212"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12066"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-17861"},{"key":"e_1_2_9_35_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2893.2007.00894.x","article-title":"Exacerbation of chronic hepatitis B infection after delivery","volume":"15","author":"Borg MJ","year":"2008","journal-title":"J Viral Hepat"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl\u20102014\u2010308211"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.patbio.2010.02.003"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12102"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12436","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12436","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T02:44:59Z","timestamp":1717987499000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,20]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1111\/jvh.12436"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12436","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,20]]}}}